Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 154

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 7
Chunk 154
---
 we believe that our cash, cash equivalents, and marketable securities will be sufficient 

91

to fund our anticipated operating and capital expenditure requirements into late-2027. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect.

Because of the numerous risks and uncertainties associated with research, development, and commercialization of our product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future capital requirements will depend on many factors, including: 

•the initiation, timing, costs, progress and results of our product candidates, including our ongoing Phase 1 clinical trials of lunresertib;

•the progress of preclinical development and possible clinical trials of our current earlier-stage programs; 

•the scope, progress, results and costs of our research programs and preclinical development of any additional product candidates that we may pursue; 

•the development requirements of other product candidates that we may pursue; 

•our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure; 

•the timing and amount of milestone and royalty payments that we are required to make or eligible to receive under our current or future collaboration agreements; 

•the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other regulatory authorities; 

•the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we or our collaborators receive marketing approval; 

•the cost of expanding, maintaining and enforcing our intellectual property portfolio, including filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; 

•the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or any of our product candidates; 

•the effect of competing technological and market developments; 

•the cost and timing of completion of commercial-scale manufacturing activities; 

•the extent to which we partner our programs, acquire or in-license other product candidates and technologies or enter into additional strategic collaborations; 

•the revenue, if any, received from commercial sales of RP-3467, RP-1664, lunresertib, camonsertib and any future product candidates for which we or our collaborators receive marketing approval; and 

•the costs of operating as a public company. 

Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through a